Biodefense
GeoVax CEO Highlights Biothreat Readiness as FIFA World Cup 2026 Approaches
GeoVax CEO David A. Dodd emphasizes the need for robust public health preparedness as the FIFA World Cup 2026 is expected to draw 6.5 million attendees amid rising infectious disease threats.
GeoVax Highlights Need for Domestic MVA Vaccine Infrastructure Amid Global Outbreaks
As WHO declares Ebola a public health emergency and mpox spreads, GeoVax emphasizes the strategic importance of scalable U.S.-based MVA manufacturing for biodefense.
Oncotelic Therapeutics Featured in Editorial Highlighting Intranasal Drug Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics' intranasal nose-to-brain delivery platform, featured in a BioMedWire editorial, addresses key challenges in CNS drug delivery for Alzheimer's disease and biodefense research by bypassing the blood-brain barrier.
Soligenix Secures Financial Stability Through 2026 to Advance Rare Disease and Biodefense Pipeline
Soligenix has strengthened its financial position with strategic capital initiatives, providing runway through 2026 to advance multiple late-stage therapeutic and vaccine candidates addressing rare diseases and biodefense needs.
Soligenix Advances Heat-Stable Ricin Vaccine Amid Global Biothreat Concerns
Soligenix Inc. is progressing with RiVax®, a heat-stable vaccine against ricin toxin, showcasing significant potential in biodefense and public safety.